Preserved in Portico This version is not peer-reviewed
Therapeutic Effects of Traditional Chinese Medicine Formula Qianlie Tongli Decoction on Chronic Prostatitis/Chronic Pelvic Pain Syndrome Induced by Peptide T2 in Mice
: Received: 16 April 2020 / Approved: 17 April 2020 / Online: 17 April 2020 (13:50:59 CEST)
: Received: 23 April 2020 / Approved: 24 April 2020 / Online: 24 April 2020 (04:30:56 CEST)
Objectives: This study was undertaken to reveal therapeutic effects and the preliminary mechanism of Chinese medicine formula Qianlie Tongli decoction (QTD) in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Methods: A total of 50 male C57BL/6 mice were randomly divided into five groups. All groups except the control group were injected subcutaneously T2 peptide emulsion, which induced the CP/CPPS model. After the induction of CP/CPPS, the model group was given 0.9% NaCl by oral gavage while low-dose, medium-dose, and high-dose groups were treated with Chinese medicine formula. Micturition habits and pain behavior of mice were analyzed for each group. Hematoxylin and eosin staining were used to investigate prostate inflammation. The serum level of tumor necrosis factor-α (TNF-α) was measured by enzyme-linked immunosorbent assay (ELISA) kit. Key findings: Chinese medicine formula significantly reduced the number of urine spots and improved pain response frequency in the medium-dose and high-dose group. The high-dose group showed reduced considerably inflammatory lesion and inflammatory cell infiltration than the low-dose and medium-dose groups. Serum levels of TNF-α in the high-dose group were significantly reduced compared with the model group. Conclusions: The results demonstrated the therapeutic effects of Qianlie Tongli decoction in CP/CPPS mice by analyzing clinically relevant symptoms (urinary tract system, pelvic pain, and prostate inflammation), and preliminary explored the inflammatory-related treatment mechanisms by measuring TNF-α.
Qianlie Tongli decoction; chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS); anti-inflammation; therapeutic effects; immunization
Medicine and Pharmacology, Urology and Nephrology
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
* All users must log in before leaving a comment